Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 279751
Licensor granted a sublicense to research and develop, including submission of grant proposals and independent funding, apply for centralized, national or other marketing authorization, manufacture, have manufacture, use, export/import, offer to sell and/or sell Berubicin.
IPSCIO Record ID: 238361
Berubicin is a novel therapy for the treatment of glioblastoma. Berubicin is one of the first anthracyclines (the most potent class of cancer drugs) to cross over the blood brain barrier and kill tumor cells in humans.
Glioblastoma is a type of astrocytoma, a cancer that forms from star-shaped cells in the brain called astrocytes. In adults, this cancer usually starts in the cerebrum, the largest part of your brain. Glioblastoma tumors make their own blood supply, which helps them grow
IPSCIO Record ID: 301547
Under the HPI License Licensor obtained the exclusive right to develop certain patented chemical compounds for use in the treatment of cancer anywhere in the world
IPSCIO Record ID: 259856
Annamycin is an anthracycline antibiotic being investigated for the treatment of cancer.
Licensor is a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on discoveries made at M.D. Anderson Cancer Center. The Licensor's clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML.